OBJECTIVES

Assess the impact of poor metabolic health on the risk of cubital tunnel

syndrome.

Clarify the effect of aggressive management of metabolic disease by GLP-

1 agonists on the risk of developing cubital tunnel syndrome.

 

INTRODUCTION

• Cubital tunnel syndrome (CuTS) is the second most common compressive

neuropathy of the upper extremity, with a reported incidence of approximately

30 per 100,000 person-years. 1

• CuTS may result in significant morbidity including: intrinsic muscle atrophy,

debilitating pain, and hand contractures, significantly impairing fine motor skills

and decreasing overall quality of life. 2

• The development of compressive neuropathies has been increasingly linked to

systemic metabolic disease. 3,4

• While diabetes is a well-established independent risk factor for compressive

neuropathies, the relationship between body mass index (BMI) and CuTS is more

complex. 3,4

• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are at the forefront of

contemporary weight-loss therapy, although their impact on peripheral

compressive neuropathies remains poorly defined.

CONCLUSIONS

• Obesity and diabetes were independently associated with increased cubital

tunnel syndrome (CuTS) risk, with diabetes demonstrating a far more robust

effect than obesity.

• Patients with concurrent obesity and diabetes exhibited the highest risk,

supporting a synergistic, or at minimum additive, effect of combined

metabolic disease on ulnar nerve vulnerability. This suggests that

cumulative metabolic burden may be more clinically relevant than either

condition in isolation.

• Among diabetic subgroups, type 1 diabetes conferred a greater risk than

type 2 diabetes, regardless of obesity status, indicating that disease

severity, chronicity, or underlying pathophysiology may further modulate

susceptibility to nerve compression.

• GLP-1 receptor agonist use was associated with an increased risk of CuTS

across nearly all metabolic subgroups, despite their established benefits in

weight reduction and glycemic control.

• Potential mechanisms include rapid weight loss leading to decreased

perineural cushioning, alterations in soft tissue support, or changes in

elbow biomechanics that increase susceptibility to ulnar nerve

compression.

• Clinically, these findings highlight the importance of heightened

surveillance for compressive neuropathies in patients with metabolic

disease, particularly for those taking GLP-1 agonists.

• Further prospective studies are needed to clarify causality, define temporal

relationships, and identify high-risk patients who may benefit from early

intervention or preventive strategies